Le Lézard
Classified in: Business, Covid-19 virus
Subjects: EARNINGS, Conference Call, Webcast, Advisory

New Mountain Finance Corporation Schedules its Fourth Quarter and Year Ended December 31, 2022 Earnings Release and Conference Call


New Mountain Finance Corporation (Nasdaq: NMFC) ("New Mountain" or "the Company") announced today that it will release financial results for the quarter and year ended December 31, 2022 on Monday, February 27, 2023 after markets close. The Company will host an earnings conference call and webcast at 10:00 am Eastern Time on Tuesday, February 28, 2023. During the live conference call, the Company's officers will review the fourth quarter and year ended December 31, 2022 performance, discuss recent events and conduct a question-and-answer session.

Fourth Quarter and Year Ended December 31, 2022 Conference Call Information
To participate in the live earnings conference call, please use the following dial-in numbers or visit the audio webcast link. To avoid any delays, please join at least fifteen minutes prior to the start of the call.

United States: (877) 443-9109
International: +1 (412) 317-1082
Live Audio Webcast

Fourth Quarter and Year Ended December 31, 2022 Conference Call Replay Information
A replay of the conference call can be accessed one hour after the end of the conference call through May 28, 2023. The full webcast replay will be available through February 28, 2024. To access the earnings webcast replay, please visit the New Mountain Investor Relations website.

United States: (877) 344-7529
International: +1 (412) 317-0088
Access Code: 3965566

ABOUT NEW MOUNTAIN FINANCE CORPORATION
New Mountain Finance Corporation is a closed-end, non-diversified and externally managed investment company that has elected to be regulated as a business development company under the Investment Company Act of 1940, as amended. The Company's investment objective is to generate current income and capital appreciation through the sourcing and origination of debt securities at all levels of the capital structure, including first and second lien debt, notes, bonds and mezzanine securities. The Company's first lien debt may include traditional first lien senior secured loans or unitranche loans. Unitranche loans combine characteristics of traditional first lien senior secured loans as well as second lien and subordinated loans. Unitranche loans will expose the Company to the risks associated with second lien and subordinated loans to the extent it invests in the "last out" tranche. In some cases, the investments may also include small equity interests. The Company's investment activities are managed by its Investment Adviser, New Mountain Finance Advisers BDC, L.L.C., which is an investment adviser registered under the Investment Advisers Act of 1940, as amended. More information about New Mountain Finance Corporation can be found on the Company's website at http://www.newmountainfinance.com.

FORWARD-LOOKING STATEMENTS
Statements included herein may contain "forward-looking statements", which relate to our future operations, future performance or our financial condition. Forward-looking statements are not guarantees of future performance, condition or results and involve a number of risks and uncertainties, including the impact of COVID-19 and related changes in base interest rates and significant volatility on our business, portfolio companies, our industry and the global economy. Actual results and outcomes may differ materially from those anticipated in the forward-looking statements as a result of a variety of factors, including those described from time to time in our filings with the Securities and Exchange Commission or factors that are beyond our control. New Mountain Finance Corporation undertakes no obligation to publicly update or revise any forward-looking statements made herein, except as may be required by law. All forward-looking statements speak only as of the time of this press release.


These press releases may also interest you

at 10:12
Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that results from the ibezapolstat Phase 2 clinical...

at 10:05
Gibson, Dunn & Crutcher LLP and Barrasso Usdin Kupperman Freeman & Sarver, LLC announce the filing of a civil rights action on behalf of Tayjha Alfred against Martin Bofill ("Bo") Duhé, the District Attorney for the 16th Judicial District of...

at 10:01
The global Control Valve market is expected to grow from USD 10.0 billion in 2024 to USD 13.0 billion by 2029, registering a CAGR of 5.4% according to a new report by MarketsandMarketstm. The global market for control valves has experienced...

at 10:00
A new report from the Health Care Cost Institute (HCCI) shows that, even with fluctuations in 2020 and 2021, per person health care spending grew from 2018 to 2022. Over the five years, average prices increased by 14% and utilization went up by about...

at 10:00
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with an entire industry chain, announced that the Phase I/II clinical study results of the novel Nectin-4-targeting ADC 9MW2821 for multiple advanced solid tumors will be presented...

at 09:49
Adyton Resources Corporation is pleased to report that on closing the recently announced C$1.5M financing, work activities on its 100% owned Feni Island Gold-Copper Project have commenced in earnest with the engagement of globally renowned...



News published on and distributed by: